Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.7% - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded up 6.7% during mid-day trading on Tuesday . The company traded as high as $5.29 and last traded at $5.26. 7,476,874 shares changed hands during trading, a decline of 54% from the average session volume of 16,084,284 shares. The stock had previously closed at $4.93.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price on the stock. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Price Performance

The firm has a 50 day moving average of $4.81 and a 200-day moving average of $6.07. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.15 billion, a P/E ratio of -2.98 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same period last year, the business earned ($0.39) earnings per share. The company's quarterly revenue was up 7.2% compared to the same quarter last year. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of RXRX. AlphaQuest LLC purchased a new position in shares of Recursion Pharmaceuticals during the first quarter valued at about $36,000. GAMMA Investing LLC boosted its stake in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC increased its stake in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $54,000. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.